清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

泊马度胺 达拉图穆马 医学 地塞米松 来那度胺 多发性骨髓瘤 内科学 肿瘤科 外科
作者
Meletios Α. Dimopoulos,Evangelos Terpos,Mario Boccadoro,Sosana Delimpasi,Meral Beksaç,Eirini Katodritou,Philippe Moreau,Luca Baldini,Argiris Symeonidis,Jelena Bila,Albert Oriol,María‐Victoria Mateos,Hermann Einsele,Ioannis Orfanidis,Tahamtan Ahmadi,Jon Ukropec,Tobias Kampfenkel,Jordan M. Schecter,Yanping Qiu,Himal Amin
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (6): 801-812 被引量:323
标识
DOI:10.1016/s1470-2045(21)00128-5
摘要

In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma. We aimed to evaluate whether daratumumab plus pomalidomide and dexamethasone would improve progression-free survival versus pomalidomide and dexamethasone alone in patients with previously treated multiple myeloma.In this ongoing, open-label, randomised, phase 3 trial (APOLLO) done at 48 academic centres and hospitals across 12 European countries, eligible patients were aged 18 years or older, had relapsed or refractory multiple myeloma with measurable disease, had an Eastern Cooperative Oncology Group performance status of 0-2, had at least one previous line of therapy, including lenalidomide and a proteasome inhibitor, had a partial response or better to one or more previous lines of antimyeloma therapy, and were refractory to lenalidomide if only one previous line of therapy was received. Patients were randomly assigned (1:1) by an interactive web-response system in a random block size of two or four to receive pomalidomide and dexamethasone alone or daratumumab plus pomalidomide and dexamethasone. Randomisation was stratified by number of previous lines of therapy and International Staging System disease stage. All patients received oral pomalidomide (4 mg, once daily on days 1-21) and oral dexamethasone (40 mg once daily on days 1, 8, 15, and 22; 20 mg for those aged 75 years or older) at each 28-day cycle. The daratumumab plus pomalidomide and dexamethasone group received daratumumab (1800 mg subcutaneously or 16 mg/kg intravenously) weekly during cycles 1 and 2, every 2 weeks during cycles 3-6, and every 4 weeks thereafter until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival in the intention-to-treat population. Safety was analysed in all patients who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov, NCT03180736.Between June 22, 2017, and June 13, 2019, 304 patients (median age 67 years [IQR 60-72]; 161 [53%] men and 143 [47%] women) were randomly assigned to the daratumumab plus pomalidomide and dexamethasone group (n=151) or the pomalidomide and dexamethasone group (n=153). At a median follow-up of 16·9 months (IQR 14·4-20·6), the daratumumab plus pomalidomide and dexamethasone group showed improved progression-free survival compared with the pomalidomide and dexamethasone group (median 12·4 months [95% CI 8·3-19·3] vs 6·9 months [5·5-9·3]; hazard ratio 0·63 [95% CI 0·47-0·85], two-sided p=0·0018). The most common grade 3 or 4 adverse events were neutropenia (101 [68%] of 149 patients in the daratumumab plus pomalidomide and dexamethasone group vs 76 [51%] of 150 patients in the pomalidomide and dexamethasone group), anaemia (25 [17%] vs 32 [21%]), and thrombocytopenia (26 [17%] vs 27 [18%]). Serious adverse events occurred in 75 (50%) of 149 patients in the daratumumab plus pomalidomide and dexamethasone group versus 59 (39%) of 150 patients in the pomalidomide and dexamethasone group; pneumonia (23 [15%] vs 12 [8%] patients) and lower respiratory tract infection (18 [12%] vs 14 [9%]) were most common. Treatment-emergent deaths were reported in 11 (7%) patients in the daratumumab plus pomalidomide and dexamethasone group versus 11 (7%) patients in the pomalidomide and dexamethasone group.Among patients with relapsed or refractory multiple myeloma, daratumumab plus pomalidomide and dexamethasone reduced the risk of disease progression or death versus pomalidomide and dexamethasone alone and could be considered a new treatment option in this setting.European Myeloma Network and Janssen Research and Development.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
空儒完成签到 ,获得积分10
5秒前
周铖完成签到 ,获得积分10
5秒前
rum完成签到 ,获得积分10
15秒前
笛卡尔的情书完成签到 ,获得积分10
22秒前
23秒前
任伟超完成签到,获得积分10
25秒前
隐形雅柔完成签到,获得积分10
27秒前
久晓完成签到 ,获得积分10
32秒前
zj完成签到 ,获得积分10
45秒前
归海一刀完成签到 ,获得积分10
45秒前
谦让的沛芹完成签到,获得积分10
54秒前
milalala完成签到 ,获得积分10
1分钟前
态度完成签到,获得积分10
1分钟前
我爱木棉完成签到 ,获得积分10
1分钟前
快乐的文博完成签到,获得积分10
1分钟前
儒雅语雪完成签到,获得积分10
1分钟前
狼来了aas完成签到,获得积分10
1分钟前
Lucas的应助被wshwx采纳,获得50
1分钟前
MOREMO完成签到,获得积分10
1分钟前
御坂10576号完成签到,获得积分10
1分钟前
魏魏完成签到 ,获得积分10
1分钟前
0_08完成签到,获得积分10
1分钟前
超男完成签到 ,获得积分10
1分钟前
1分钟前
冰虚完成签到 ,获得积分10
1分钟前
wshwx发布了新的文献求助50
2分钟前
2分钟前
kkyy发布了新的文献求助10
2分钟前
Xulyun完成签到 ,获得积分10
2分钟前
小元元完成签到 ,获得积分10
2分钟前
2分钟前
gzhy完成签到,获得积分10
2分钟前
儒雅的白曼完成签到,获得积分10
2分钟前
虚幻念寒完成签到 ,获得积分10
2分钟前
昏睡的友菱完成签到,获得积分10
2分钟前
dada完成签到,获得积分10
2分钟前
wayne完成签到 ,获得积分0
2分钟前
2分钟前
科研通AI6.3的应助被wshwx采纳,获得50
2分钟前
qiongqiong完成签到 ,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180034
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808628
捐赠科研通 7776034
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557405
邀请新用户注册赠送积分活动 2478998